Alumis: Betting on Envudeucitinib — A High-Risk, High-Reward Long Into Clinical Catalysts
Alumis built a valuation around envudeucitinib after two positive Phase 3 psoriasis readouts. The next 3-6 months — pivotal lupus data in Q3 and an expected NDA in Q4 2026 — will tell whether those results translate into a commercial opportunity. This trade idea lays out a long entry with clear stop and target, plus the risks that could unravel the…